XML 15 R2.htm IDEA: XBRL DOCUMENT v3.20.4
BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 9,925 $ 13,644
Restricted cash 363 270
Marketable securities 186,350 125,681
Interest and other receivables 722 802
Prepaid and other current assets 2,497 1,211
Total current assets 199,857 141,608
Noncurrent marketable securities 63,387 19,651
Property and equipment, net 658 408
Operating leases, right-of-use assets 5,295 2,497
Deposits and other assets 1,531 1,353
Total assets 270,728 165,517
Current liabilities:    
Accounts payable 6,919 1,181
Accrued compensation and benefits 8,218 4,830
Amount due to Janssen Biotech, Inc.   14,269
Operating lease liabilities 878 354
Accrued liabilities 14,925 7,528
Total current liabilities 30,940 28,162
Noncurrent operating lease liabilities 4,799 2,200
Noncurrent debt 24,042  
Total liabilities 59,781 30,362
Commitments and contingencies
Stockholders' equity:    
Preferred stock, $0.001 par value; 3,000,000 shares authorized; no shares issued and outstanding at December 31, 2020 and 2019
Common stock, $0.001 par value; 450,000,000 shares authorized; 310,566,853 and 199,814,581 shares issued and outstanding at December 31, 2020 and 2019, respectively 310 200
Additional paid-in capital 1,366,188 1,214,835
Accumulated deficit (1,155,629) (1,080,012)
Accumulated other comprehensive gain 78 132
Total stockholders' equity 210,947 135,155
Total liabilities and stockholders' equity $ 270,728 $ 165,517